Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Community Perspectives on Integrating and Interpreting Molecular Testing Results in NSCLC

October 17th 2022

Drs Ramkumar and Morganstein discuss the challenges they face with integrating and organizing molecular testing results into electronic medical records, how they address non–small cell lung cancer test results with patients, and their hopes for the future of pathology at their institutions.

Unmet Needs in NSCLC Therapy

October 17th 2022

Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.

Dr. Iams on Small Cell Lung Cancer Subtyping in Clinical Practice

October 17th 2022

Wade T. Iams, MD, discusses the potential for providing small cell lung cancer subtyping in clinical practice.

The Role of Adjuvant Immunotherapy in the Treatment of Resectable NSCLC

October 17th 2022

Vamsidhar Velcheti, MD, summarizes recent data on adjuvant immunotherapy treatment in resectable NSCLC.

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The NEOCoast Trial

October 17th 2022

Dr Myung-Ju Ahn describes the unique design and outcomes of the NEOCoast study that is evaluating immunotherapy regimens in the neoadjuvant and adjuvant settings.

Updates in the Treatment of Stage I-IIIA NSCLC

October 17th 2022

The panel reviews updates in the treatment of stage I-IIIA NSCLC and discusses its impact in clinical practice.

Is There a Role for Liquid Biopsies in Early NSCLC?

October 17th 2022

Ignacio Wistuba, MD, leads the discussion on the role of liquid biopsies for molecular testing in early NSCLC.

Is Therapeutic Value a New Name for Medical Paternalism?

October 14th 2022

What is noteworthy is the process whereby this patient employs both objective data and his personal beliefs to declare what he values.

FDA Approval Insights: Selpercatinib in RET Fusion–Positive Solid Tumors

October 13th 2022

Dr Subbiah discusses the significance of the FDA approval of selpercatinib in RET fusion–positive non–small cell lung cancer, thyroid cancer, and other solid tumors.

Sotorasib/BBP-398 Combo Snags FDA Fast Track Status for KRAS G12C–Mutated NSCLC

October 12th 2022

A combination regimen comprised of sotorasib and BBP-398 has been awarded a fast track designation from the FDA for use as a potential therapeutic option in adult patients with previously treated, KRAS G12C–mutated, metastatic non–small cell lung cancer.

Avelumab and Axitinib Elicits Responses in Advanced Thymoma and Thymic Carcinoma

October 12th 2022

The combination of avelumab and axitinib demonstrated promising response rates and progression-free survival and an expected safety profile in pretreated patients with advanced type B3 thymoma and thymic carcinoma, according to findings from an ongoing phase 2 study.

Enhancing Communication Among the Multidisciplinary Care Team

October 12th 2022

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share standards of communication among the care team at their clinical practice sites.

Challenges With and Strategies for Tissue Procurement in NSCLC

October 12th 2022

Drs Benjamin Levy, Neil Morganstein, and Bhuvana Ramkumar discuss challenges of procuring for molecular testing in patients with NSCLC.

Expert Puts the Accent on Curative Potential in NSCLC Landscape

October 12th 2022

Mark A. Socinski, MD, has become internationally known for his research into the molecular drivers of lung cancer and his contributions to the refinement of multidisciplinary care.

Major Adverse Events of Anti-HER2 Therapies

October 10th 2022

Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.

HER2-Targeted Therapies in NSCLC

October 10th 2022

Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.

Investigators Seek to Resolve the “Obesity Paradox” in Lung Cancer

October 10th 2022

Smoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.

Optimizing the Role of Neoadjuvant Immunotherapy in Resectable NSCLC

October 7th 2022

Drs Vamsidhar Velcheti and Solange Peters discuss the optimum length for immunotherapy treatment in resectable NSCLC, highlighting the issue of payer authorizations.

Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials

October 7th 2022

Oncologists explain data from the NADIM II and AEGAN clinical trials investigating treatments for neoadjuvant immunotherapy in resectable NSCLC.

Durvalumab, Tremelimumab, and Chemotherapy Elicit Promising Long-Term OS Rates in NSCLC

October 6th 2022

Melissa L. Johnson, MD, expands on the updated data from the POSEIDEN trial, the rationale for investigating the combination, and what these results mean for the treatment of metastatic non–small cell lung cancer.